Evidence map›Paper›PMID 32822571›Full record

ArticleCell2020

Myeloid Cells TREM Down Anti-tumor Responses.

Aimée Bugler-Lamb, Martin Guilliams

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Defining and targeting tumor-associated macrophages in malignant mesothelioma.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Aimée Bugler-LambLaboratory of Myeloid Cell Biology in Tissue Homeostasis and Regeneration, VIB-UGent Center for Inflammation Research, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Martin GuilliamsLaboratory of Myeloid Cell Biology in Tissue Homeostasis and Regeneration, VIB-UGent Center for Inflammation Research, Ghent, Belgium; Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium. Electronic address: martin.guilliams@ugent.vib.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of Cell, Molgora et al. and Katzenelenbogen, Sheban, Yalin, et al. highlight the novel role of TREM2 in shaping the immunosuppressive profile of tumor-associated myeloid cells and report that complementing immune-checkpoint therapy with TREM2 blockade induces stronger anti-tumor immune responses and reduces tumor growth.

Indexed as

NeoplasmsRNA, Small CytoplasmicHumansMembrane GlycoproteinsMyeloid CellsReceptors, ImmunologicSingle-Cell AnalysisTriggering Receptor Expressed on Myeloid Cells-1Membrane GlycoproteinsReceptors, ImmunologicRNA, Small CytoplasmicTREM2 protein, humanTriggering Receptor Expressed on Myeloid Cells-1

Identifiers

PMID32822571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.